Early clinical evidence suggests that DMT can produce rapid, significant reductions in depression symptoms, but the research is still in early stages. The most rigorous trial to date, a phase 2a placebo-controlled study published in Nature Medicine, found that a single intravenous dose of DMT paired with therapeutic support led to meaningful improvement in depression scores within one week, with effects lasting up to three months in some participants and up to six months in others.
That said, DMT is not an approved treatment for depression anywhere in the world. It remains a Schedule I controlled substance in the United States. What exists right now is promising but preliminary data from small trials, not the kind of large-scale evidence needed for clinical use.
What the Clinical Evidence Shows
The strongest evidence comes from a 2025 phase 2a trial that enrolled 34 adults with moderate-to-severe major depressive disorder. Participants received either a single 21.5-milligram intravenous infusion of DMT or a placebo, delivered over 10 minutes, alongside psychotherapeutic support. At two weeks, those who received DMT showed significantly greater improvement on a standard depression rating scale compared to placebo. The difference was clear enough to reach statistical significance even in this small sample.
Response rates tell the story in more practical terms. At two weeks, 35% of DMT recipients had at least a 50% reduction in their depression scores, compared to 12% in the placebo group. Remission, meaning symptoms dropped to minimal levels, occurred in 29% of the DMT group versus 12% on placebo. When participants were followed for six months (in an open-label phase where everyone knew they were getting DMT), remission and response rates climbed to 40% and 44%, respectively. Notably, there was no meaningful difference between people who received one dose and those who received two, suggesting a single session may be sufficient.
The speed of improvement is one of the more striking findings. Depression scores began dropping within 24 hours and showed significant improvement by one week. Traditional antidepressants typically take four to six weeks to reach full effect.
How DMT Affects the Brain
DMT activates serotonin 2A receptors in the brain, the same target that psilocybin and LSD act on. But the downstream effects go well beyond simply boosting serotonin signaling. The compound appears to trigger a cascade of structural changes in brain cells: neurons sprout new branches, form new connection points, and build new synapses. These changes are collectively called neuroplasticity, and they mirror what researchers see with ketamine, another fast-acting antidepressant.
Animal research has added another layer to this picture. In stress-induced depression models, a single dose of DMT increased the integration of newly born neurons in the hippocampus, a brain region critical for mood regulation and memory. It also reduced the number of abnormally wired new neurons, essentially improving the quality of new brain cell connections, not just the quantity.
At the network level, DMT temporarily disrupts the default mode network, a group of brain regions that tend to be overactive in depression. This network is associated with rumination, self-referential thinking, and the kind of repetitive negative thought loops that characterize depressive episodes. The acute disruption appears to be followed by a longer-term normalization of activity in these regions. At a psychological level, people report decreased negative emotions, increased positive feelings, and a greater sense of connection to themselves and others.
How DMT Compares to Psilocybin
Both DMT and psilocybin act on the same receptor system and produce similar types of neuroplastic changes. The critical difference is duration. Psilocybin’s effects take 30 to 60 minutes to begin and last four to six hours. DMT’s effects, when given intravenously, begin almost instantly and last only 15 to 30 minutes.
This is a practical advantage. A psilocybin therapy session requires a full day of clinical supervision. A DMT session could fit into a fraction of that time, reducing the cost and staffing burden that make psychedelic-assisted therapy expensive to deliver. For the same reason, it could be more scalable if it reaches approval.
Psilocybin has a larger evidence base at this point. A phase 2 trial of 233 participants with treatment-resistant depression found significant increases in response and remission after a single oral dose at three weeks, though those benefits did not hold at three months. DMT’s smaller trial showed effects lasting longer in some participants, but direct comparisons between the two compounds in head-to-head trials have not been conducted.
What a DMT Therapy Session Looks Like
DMT is not handed out as a prescription. In clinical trials, it is administered in a controlled medical setting as part of a structured psychotherapy protocol. Before the dosing session, participants go through preparation sessions designed to build trust with their therapists, set intentions, and learn what to expect from the psychedelic experience.
On dosing day, the DMT is infused intravenously over about 10 minutes. The psychedelic experience itself lasts roughly 15 to 30 minutes. Therapists remain present throughout, providing support but generally not directing the experience. In the days and weeks that follow, participants return for integration sessions where they process what they experienced and work on translating any insights into lasting changes in thinking and behavior. The total number of psychedelic sessions in most protocols ranges from one to three, spread over several weeks.
Side Effects and Safety Concerns
In clinical settings, DMT’s side effects have generally been mild and short-lived. The most commonly reported issues include nausea, headache, anxiety, and temporary psychological discomfort during the experience itself. Heart rate and blood pressure tend to rise briefly after administration but return to normal within about 90 minutes. One case report documented a more notable cardiovascular reaction, with a participant experiencing a drop in heart rate and blood pressure after an intravenous dose, though this was an isolated finding.
The psychological intensity of the experience is itself a risk factor. DMT produces powerful alterations in perception, thought, and emotion. For most people in a supervised setting, this is manageable. But certain populations are excluded from trials for good reason. People with a current or past psychotic disorder, bipolar disorder, or a first-degree relative with psychosis are not eligible. The same goes for people with uncontrolled high blood pressure, those currently pregnant or breastfeeding, or anyone using medications that could interact with the compound. These exclusions exist because the safety data simply does not cover these groups, and the theoretical risks (triggering a psychotic episode, for instance) are too serious to test casually.
Where Things Stand Now
DMT for depression is in the middle stages of clinical development. The phase 2a results are encouraging, but 34 participants is a small trial. Larger phase 2b and phase 3 trials are needed to confirm whether these effects hold up across more diverse patient populations and longer follow-up periods. A separate compound, 5-MeO-DMT (a related but chemically distinct molecule), is also being tested in a phase 2b trial for treatment-resistant depression, with participants inhaling the drug rather than receiving it intravenously.
If the larger trials succeed, regulatory approval would still be years away. In the meantime, DMT remains illegal outside of approved research settings in most countries. The underground and ceremonial use of DMT, particularly in ayahuasca, carries additional risks from uncontrolled dosing, lack of medical screening, and absence of therapeutic support. The clinical results, while promising, were achieved under conditions that are difficult to replicate outside a research environment.